2014

17/12/2014
ABLYNX OPENS RECRUITMENT FOR FIRST-IN-INFANT PHASE IIa STUDY WITH ITS ANTI-RSV NANOBODY, ALX-0171


08/12/2014
ADDITIONAL CLINICAL DATA FROM THE PHASE II STUDY WITH ABLYNX'S ANTI-vWF NANOBODY, CAPLACIZUMAB, PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING


26/11/2014
ABLYNX DEMONSTRATES BIOEQUIVALENCE BETWEEN LIQUID AND LYOPHILISED FORMULATIONS OF ITS ANTI-vWF NANOBODY, CAPLACIZUMAB


18/11/2014
ABLYNX APPOINTS JOHAN HEYLEN AS CHIEF COMMERCIAL OFFICER


17/11/2014
ABLYNX TO PRESENT AT THE JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE IN LONDON


14/11/2014
ABLYNX TO PRESENT DATA ON ITS ANTI-IL-6R NANOBODY, DEVELOPED IN PARTNERSHIP WITH ABBVIE, AT THE AMERICAN COLLEGE OF RHEUMATOLOGY ANNUAL MEETING


13/11/2014
ABLYNX ANNOUNCES ITS BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2014


06/11/2014
ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT RESULTS WITH ANTI-RSV NANOBODY, ALX-0171, AT 9th INTERNATIONAL RESPIRATORY SYNCYTIAL VIRUS SYMPOSIUM


23/10/2014
ABLYNX'S ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE DEMONSTRATES A BIOAVAILABILITY OF MORE THAN 80% AFTER SUBCUTANEOUS INJECTION


21/10/2014
ABLYNX ANNOUNCES WARRANT EXERCISE


05/09/2014
ABLYNX ESTABLISHES SPONSORED LEVEL I ADR PROGRAMME IN THE UNITED STATES


01/09/2014
ABLYNX SIGNS EXCLUSIVE LICENSE AGREEMENT WITH EDDINGPHARM TO DEVELOP AND COMMERCIALISE ITS ANTI-TNFa NANOBODY IN GREATER CHINA


28/08/2014
ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2014


21/08/2014
ABLYNX WILL ANNOUNCE ITS HALF-YEAR RESULTS FOR 2014 WITH WEBCAST


13/08/2014
ABLYNX AWARDED €2.1 MILLION GRANT TO SUPPORT DEVELOPMENT OF NOVEL NANOBODIES® FOR OCULAR APPLICATIONS


18/07/2014
ABLYNX ANNOUNCES WARRANT EXERCISE


15/07/2014
EURONEXT INTRODUCES SPOTLIGHT OPTIONS ON ABLYNX


08/07/2014
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")


03/07/2014
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")


30/06/2014
ABLYNX SUCCESSFULLY RAISES €41.7 MILLION


30/06/2014
ABLYNX TO RAISE CAPITAL VIA A PRIVATE PLACEMENT OF NEW SHARES


20/06/2014
ABLYNX WINS TRANSACTION OF THE YEAR AT THE 2014 EUROPEAN MEDISCIENCE AWARDS


19/06/2014
ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT DATA FOR ANTI-KV1.3 NANOBODIES AT TWO LEADING ION CHANNEL MEETINGS


17/06/2014
ABLYNX'S ANTI-vWF NANOBODY, CAPLACIZUMAB, ACHIEVES CLINICAL PROOF-OF-CONCEPT IN PHASE II TITAN STUDY


10/06/2014
ABLYNX TO PRESENT ADDITIONAL DATA ON ALX-0061, THE ANTI-IL-6R NANOBODY BEING DEVELOPED IN PARTNERSHIP WITH ABBVIE, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY


27/05/2014
ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE


20/05/2014
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")


14/05/2014
ABLYNX ANNOUNCES Q1 2014 BUSINESS UPDATE


13/05/2014
ABLYNX TO PRESENT AT THE 2014 UBS GLOBAL LIFE SCIENCES CONFERENCE


06/05/2014
ABLYNX'S INHALED ANTI-RSV NANOBODY, ALX-0171, SUCCESSFULLY COMPLETES TWO FURTHER PHASE I CLINICAL STUDIES


30/04/2014
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")


23/04/2014
ABLYNX ANNOUNCES WARRANT EXERCISE


23/04/2014
ABLYNX INITIATES PHASE I BIOAVAILABILITY STUDY WITH SUBCUTANEOUS FORMULATION OF ITS ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE


27/02/2014
ABLYNX ANNOUNCES 2013 FULL YEAR RESULTS


20/02/2014
ABLYNX WILL ANNOUNCE FULL YEAR RESULTS 2013 WITH WEBCAST


03/02/2014
ABLYNX ANNOUNCES WORLDWIDE CANCER IMMUNOTHERAPY DISCOVERY COLLABORATION AND LICENSING AGREEMENT WITH MERCK


20/01/2014
ABLYNX ANNOUNCES WARRANT EXERCISE


13/01/2014
ABLYNX TO PRESENT AT THE 32nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE AND TO PROVIDE AN UPDATE ON ITS TTP PROGRAMME


Click the button below to subscribe to the Ablynx news service
Subscribe